1029P - Cisplatin + vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): a final report on 60 cases

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Cytotoxic agents
Head and Neck Cancers
Therapy
Biological therapy
Presenter Oliviero Ostellino
Citation Annals of Oncology (2014) 25 (suppl_4): iv340-iv356. 10.1093/annonc/mdu340
Authors O. Ostellino1, M. Garzaro2, F. Pedani1, M. Airoldi1, E. Bellini1, L. Raimondo2, G. Pecorari2
  • 1Sc Oncologia 2, Città della Saluta e della Scienza - Torino, 10128 - Torino/IT
  • 2Surgical Sciences Department, 1st ENT Division - University of Turin, 10126 - Turin/IT

Abstract

Aim

RMSGM are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP + VNB as a first- or second-line scheme.

Methods

Sixty patients between 2001 and 2008, affected by RMSGM were enrolled in this cohort prospective study; they received the following first- or second-line CT, for a maximum of 6 cycles: DDP at 80 mg/m2 on d 1 + VNB at 25 mg/ m2 on d 1 and 8, at 3-wk intervals.

Results

Seventy percent of the patients received DDP + VNB as the first-line CT and 30% of them received it as the second-line CT. After 5 cycles (median) of first-line DDP + VNB, 7% of the patients achieved a CR, 24% achieved a PR, 33% achieved an NC and 36% achieved a PD. After 4 cycles (median) of second-line CT, 0 patients achieved a CR, 5% achieved a PR, 33% achieved an NC and 62% achieved a PD. The median OS period was 10 months for those who received the first-line CT and 4 months for those who received the second-line CT. The best ORR (54%) and median survival were observed, during first line treatment, in adenocarcinomas, whereas undifferentiated tumours were unresponsive with a poor median survival (4.6 months).

Conclusions

Adenocarcinomas show the best response and prognosis with DDP + VNB scheme that seems to be an effective and well-tolerated first-line CT for RMSGM, whereas it has only low palliative activity as a second-line CT.

Disclosure

All authors have declared no conflicts of interest.